Clinical Trials Sponsored by Revalesio Corporation

Total 6454 results

Masimo Corporation

Terminated

Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program

Opioid Use

Canada
Incyte Corporation

Active, not recruiting

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Melanoma

United States, Australia
Incyte Corporation

Completed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Atopic Dermatitis

United States, Canada
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Incyte Corporation

Active, not recruiting

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Metastatic Merkel Cell Carcinoma

United Kingdom, United States, Germany, Canada, Czechia, Italy, France, Spain, Switzerland, Australia, Poland, Hungary
Incyte Corporation

Active, not recruiting

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Hand Eczema

United States, Poland, Canada, Germany
Insulet Corporation

Completed

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes (Evolution)

Diabetes Mellitus

New Zealand
Incyte Corporation

Completed

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Cytokine Release Syndrome

United States
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Erchonia Corporation

Completed

Human Factors Testing for OTC Use of the Erchonia® LunulaLaser

Onychomycosis

United States
Masimo Corporation

Completed

Performance of Masimo MightySat Pulse Oximeter in Differing Levels of Skin Pigmentation

Healthy

United States
Healionics Corporation

Completed

Evaluation of STARgraft-2 for Hemodialysis Access

End Stage Renal Disease

Paraguay
Glaukos Corporation

Active, not recruiting

iStent Inject New Enrollment Post-Approval Study

Glaucoma | Glaucoma, Open-Angle

United States
Cerus Corporation

Active, not recruiting

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Anemia

United States
Pulmonx Corporation

Active, not recruiting

Zephyr Valve Registry (ZEVR) (ZEVR)

Emphysema

United States
Incyte Corporation

Active, not recruiting

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma (LIMBER)

Myelodysplastic Syndromes | Multiple Myeloma | Anemia

United States, France, Italy
Seikagaku Corporation

Completed

PK and Safety of SI-722 in IC/BPS

Interstitial Cystitis | Bladder Pain Syndrome

United States
LUTRONIC Corporation

Terminated

Lutronic PicoPlus Exploratory Clinical Trial

Melasma | Tattoo; Pigmentation | Benign Pigmented Lesion

United States
Incyte Corporation

Active, not recruiting

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors

France, Spain, United States, China, United Kingdom, Lithuania, Germany, Ukraine, Finland, Italy, Belgium, Australia, Bulgaria, Latvia, New Zealand, Poland
LUTRONIC Corporation

Completed

Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning

Muscle Stimulation | Fat Necrosis

United States
PhytoHealth Corporation

Active, not recruiting

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Survival | Cancer-related Fatigue | Tumor, Esophageal

Taiwan
PhytoHealth Corporation

Terminated

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Quality of Life | Fatigue | Complementary

Taiwan
PhytoHealth Corporation

Completed

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

Fatigue

Taiwan
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Topcon Corporation

Enrolling by invitation

Screening Protocol

Glaucoma

United States
Incyte Corporation

Active, not recruiting

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Breast Cancer | Pancreatic Cancer | Lung Cancer | Colorectal Cancer (CRC)

United States
Yuhan Corporation

Completed

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

Diabetes Mellitus, Type 2 | Neuropathic Pain

Korea, Republic of
Incyte Corporation

Available

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

STAT1 Gain-of-Function Disease
Yuhan Corporation

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

Arterial Occlusive Diseases | Intermittent Claudication

Korea, Republic of
Mannkind Corporation

Completed

Afrezza® Dosing Optimization Study (DOS)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Yuhan Corporation

Completed

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Non-small Cell Lung Cancer
Tomey Corporation

Completed

Comparative Study of the TOMEY Specular Microscope EM-4000 and the Konan CellChek XL

Corneal and Endothelial Cell Measurements
Irrimax Corporation

Completed

Retrospective Independent Safety Review of Closed Irrisept Study

Adverse Events

United States
Allievex Corporation

Enrolling by invitation

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

MPS III B

United States, Germany, Turkey, United Kingdom, Colombia
Axogen Corporation

Completed

Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE)

Symptomatic Neuroma | Chronic Nerve Pain | Morton's Neuroma

United States
Admetsys Corporation

Active, not recruiting

Insulin Balanced Infusion System

Hyperglycemia | Diabetes

United States
Incyte Corporation

Completed

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Vitiligo

United States, Canada, Poland, Spain, Germany, Bulgaria, France, Netherlands
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Glaukos Corporation

Completed

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Seikagaku Corporation

Completed

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

Dry Eye Syndromes

United States
Genelux Corporation

Temporarily not available

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) | Acute Myeloid Leukemia (6 Patients)

United States
Pulmonx Corporation

Completed

Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) (LIBERATE)

Emphysema

United States, Netherlands, United Kingdom, Brazil
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
Pulmonx Corporation

Active, not recruiting

Zephyr Etude Post-Inscription (French Registry)

Emphysema or COPD

France
Incyte Corporation

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Hemodialysis | Renal Impairment

United States
Seikagaku Corporation

Completed

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

Dry Eye Syndromes

United States
Spectranetics Corporation

Completed

STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR) (ILLUMENATE)

Peripheral Arterial Disease

Belgium, Germany, New Zealand, France, United Kingdom, Australia, Poland, Austria, Italy, Spain
Erchonia Corporation

Withdrawn

Effect of Erchonia Laser on Erectile Dysfunction

Erectile Dysfunction

United States
Seikagaku Corporation

Completed

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Lumbar Disc Disease | Intervertebral Disc Disease

United States

Clinical Trials Sponsored by Revalesio Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations